23 results about "Geographic atrophy" patented technology

Embodiments disclosed herein generally relate to predicting geographic-atrophy lesion growth and / or geographic atrophy lesion size in an eye. The predictions can be generated by processing a data object using a neural network. The data object may include a three-dimensional data object representing a depiction of at least part of the eye or a multi-channel data object representing one or more decorresponding pictions of at least part of the eye. The neural network can include a convolutional multi-task neural network that is trained to learn features that are predictive of both lesion-growth and lesion-size outputs.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

An electronic device is disclosed. The device receives retinal images and patient data corresponding to the retinal images. The device can train a first machine learning model (“model”) based on a first group of the retinal images and patient data corresponding to the first group and a second model based on a second group of the retinal images and patient data corresponding to the second group. The electronic device can generate a first prediction based on the first subset of a third group of the retinal images and a second prediction based on the second subset of the third group. After training the first model and the second model, the device can train a third model to predict a geographic atrophy progression in an eye of a patient based on the first and second predictions, the first and second subsets, and patient data corresponding to the first and second subset.

Provided herein are systems utilizing machine learning in detecting geographic atrophy. The system can include at least one processor, a memory, and a computing platform including the at least one processor and the memory. The computing platform can be configured to receive volumetric scan images, determine a position of each of the volumetric scan images, generate, using a trained detection algorithm, a probabilistic likelihood that each scan is informative of geographic atrophy or neovascular age-related macular degeneration, include high probability scans in a dataset, determine, using the included scans in the dataset, whether geographic atrophy or neovascular age-related macular degeneration is present or likely to occur, and output, by the detection algorithm, information indicating whether or not geographic atrophy or neovascular age-related macular degeneration is present or likely to occur.

This disclosure provides a method and system for evaluating geographic atrophy (GA) using a custom machine learning model. A set of fundus autofluorescence (FAF) images of a subject is received. Input to the machine learning model is generated using multiple FAF images. The input includes a subset of features selected from a plurality of image features. The plurality of image features includes at least one of a plurality of shape features and a plurality of texture features. The selection of the subset of features from the plurality of features is based on evaluating the performance of a set of trained models used to process at least two different combinations of the plurality of features. A set of geographic atrophy (GA) progression parameters is predicted based on the input via the custom machine learning model.

Methods of treating ocular diseases such as age-related macular degeneration may include the administration of peptides comprising complement factor H and factor H-like protein domains to reduce an amount of geographic atrophy in a subject in need thereof. These methods may be administered by intraocular, intervascular or subcutaneous injection.

Avacincaptad pegol, also known under the trademarks Izervay or Zimura, is a molecule comprising an aptamer sequence and a polyethylene glycol polymer (PEG) -moiety. The aptamer sequence binds to complement C5-protein, which C5 protein is known to be involved in many eye diseases. Avacincaptad pegol is approved to treat Age-related Macular Degeneration (AMD) secondary to Geographic Atrophy (GA) and is applied by intravitreal injection into the eye. The pharmaceutical product is currently only offered as a liquid in a vial. This patent application discloses Avacincaptad in a more stable presentation, namely in a pre-filled syringe, which surprisingly results in very significantly improved stability of the product.

A method, system, and computer program product for evaluating a geographic atrophy lesion. An image of a geographic atrophy (GA) lesion is received. A first set of values is determined for a set of shape features using the image. A second set of values is determined for a set of textural features using the image. GA progression for the GA lesion is predicted using the first set of values and the second set of values.

This disclosure provides peptide based compounds, compositions, and methods to treat medical disordeds, such as complement-mediated disorders, including complement C1s-mediated disorders, such as acute antibody-mediated rejection, amyotrophic lateral sclerosis, autoimmune blistering disease, bullous pemphigoid, geographic atrophy, or Guillain-Barre Syndrome, comprising administering to a subject in need thereof a therapeutically effective amount of the compound.

The present disclosure relates to RNAi agents able to inhibit Complement Factor B (CFB) gene expression. Also disclosed are pharmaceutical compositions that include CFB RNAi agents and methods of use thereof. The CFB RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the in vivo delivery to hepatocyte cells. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), Anti-Glomerular Basement Membrane disease (anti-GBM), ischemia reperfusion injury and T-cell mediated rejection (TCMR) in kidney transplantation, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD), including early and / or intermediate AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated diseases.

Aspects of the present disclosure relate to compositions and methods for modulating the translation of one or more RNA transcripts (e.g., mRNA transcripts) in a cell or subject. The present disclosure is based, in part, on isolated nucleic acids that bind to an mRNA transcript of a gene involved in L-serine biosynthesis, such as serine palmitoyltransferase long chain base subunit 1 (SPTLC1). In some embodiments, the compositions of the present disclosure are useful for the treatment of diseases or conditions associated with dysregulation of L-serine biosynthesis, such as retinal diseases (e.g., MacTel2 and age-related macular degeneration (AMD), such as AMD with geographic atrophy), HSAN1 (e.g., HSAN1 (a)), diabetic retinopathy, peripheral neuropathy (e.g., neuropathy), and the treatment of diseases or conditions associated with dysregulation of L-serine biosynthesis, such as retinal diseases (e.g., MacTel2 and age-related macular degeneration (AMD), such as AMD with geographic atrophy). ), neurodegenerative disorders (e.g., Parkinson's disease, Friedel's ataxia, motor neuron disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), etc.), spasmodic paraplegia or psychiatric disorders (e.g., neurodegenerative disorders, neurodegenerative disorders, etc. ), resistant depression, refractory depression, schizophrenia, and / or refractory schizophrenia.

A method and system for assessing geographic atrophy in the retina is provided, comprising: receiving a set of fundus autofluorescence (FAF) images of the retina at a machine learning system; receiving a set of optical coherence tomography (OCT) images of the retina at a machine learning system; and predicting lesion growth rates for geographic atrophy lesions in the retina using the set of FAF images and the set of OCT images via the machine learning system.

The invention relates to a construction method and application of an animal model with retina geographic atrophy (GA) accompanied by choroidal neovascularization (CNV) symptoms. According to the method, sodium iodate is injected at multiple points in the subretinal space of cynomolgus monkeys, so that the retina has typical and clinically close retinopathy GA and CNV symptoms, and the blank of animal models for preclinical evaluation of multi-target drugs for treating GA and CNV at present is filled.

Disclosed is a method of treating a patient with Geographic Atrophy or with wet Age-related Macular Degeneration or Choroidal Neovascularization. Also disclosed is a method of delaying the progression of vision loss in a patient with Geographic Atrophy or with wet Age-related Macular Degeneration or Choroidal Neovascularization. The methods comprise administering an effective amount of gildeuretinol acetate to the patient.

Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and / or macular telangiectasia.

Recombinant AAV (rAAV) comprising a variant adeno-associated virus (AAV) capsid and a transgene encoding a human factor H variant is provided. Also provided are a method for delivering the transgene to the retina, and a method for treating dry age-related macular degeneration and geographic atrophy secondary to age-related macular degeneration by contacting retinal cells with rAAV. The variant AAV capsid protein may contain a peptide insertion ("heterogeneous peptide" or "peptide insertion") of about 7 to 20 amino acids within the GH loop of the capsid protein, preferably within the surface-exposed region of the GH loop, compared to the corresponding parental AAV capsid protein.

This article discloses a method for treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

The present disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions comprising the CFB RNAi agents and methods of using the same are also disclosed. The CFB RNAi agents disclosed herein can be conjugated to targeting ligands, including ligands comprising N-acetylgalactosamine, to facilitate in vivo delivery to hepatocytes. RNAi agents may be used in methods of treating diseases, disorders or symptoms mediated in part by CFB gene expression, the diseases, conditions or symptoms include IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane disease (anti-GBM), ischemia-reperfusion injury and T cell mediated rejection in renal transplantation, anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis, age-related macular degeneration (AMD), and the like. , including early and / or mid-term AMD, map atrophy (GA), glaucoma, Doyne cellular retinal dystrophy, paroxysmal sleep hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), preeclampsia, rheumatoid arthritis (RA), and / or other complement-mediated diseases.

Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and / or macular telangiectasia.

Aspects of the disclosure relate to compositions and methods for modulating levels, transcription, splicing, and / or translation of one or more RNA transcripts (e.g., mRNA transcripts) in a cell or subject. The disclosure is based, in part, on isolated nucleic acids that bind to mRNA transcripts of genes involved in neuroinflammation, for example complement component C3 (C3). In some embodiments, compositions of the disclosure are useful for treating diseases or disorders associated with neuroinflammation, such as dry age-related macular degeneration (dry AMD) (e.g., dry AMD with geographic atrophy), multiple sclerosis (MS), peripheral neuropathies (e.g., Guillain Barr syndrome (GBS), Chronic inflammatory demyelinating polyneuropathy (CIDP), etc.), neuromyelitis optica (NO), myasthenia gravis (MG), Alzheimer's disease, frontotemporal dementia (FTD), iatrogenic neuroinflammation (e.g., inflammation associated with adeno-associated virus administration, ASO administration, antibody administration (such as Amyloid-Related Imaging Abnormalities (ARIA) neuroinflammation), etc.), and acute neuronal injury (e.g., traumatic brain injury (TBI), spinal cord injury, stroke, etc.).

Novel anti-C3 and anti-C5 antibodies are provided that can modulate complement activity by specifically binding to human complement factors C3, C3a, C3b, and / or C5. Recombinant AAVs (rAAVs) containing variant adeno-associated virus (AAV) capsids and transgenes encoding anti-C3 and / or anti-C5 antibodies are also described herein. Methods for delivering transgenes to the retina by contacting retinal cells with rAAVs, as well as methods for treating atrophic age-related macular degeneration and geographic atrophy secondary to age-related macular degeneration disorders, are also provided.

A method implemented by one or more computing devices includes receiving fundus autofluorescence (FAF) image data of a subject's retina. The FAF image data includes a first FAF image associated with a first time point. An image input for a deep learning system is generated using the FAF image data. A predicted growth output of geographic atrophy (GA) lesions in the retina is generated via the deep learning system using the image input. The predicted growth output is associated with at least one future time point after the first time point.